Abstract Library

#4631 Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,

#4434 Treatment approaches for gastroenteropancreatic neuroendocrine neoplasms: A twelve-year experience at a single centre in Colombia

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) have multiple treatment options, but their availability varies by cost.

Conference:

Presenting Author: Molina-Pimienta L

Authors: Molina-Pimienta L, Cuellar A, Tapiero-Garcia M, Romero-Rojas A, Sanchez-Castillo J,

Keywords: neuroendocrine tumour, Kaplan-Meier analysis, treatment, Lutetium-177, surgery,

#4419 Real-world outcomes in patients with gastroenteropancreatic neuroendocrine neoplasms at a cancer centre in a middle-income country

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are rare tumours that are increasing in prevalence. However, the epidemiology of GEP-NENs in Latin America is not well understood.

Conference:

Presenting Author: Molina-Pimienta L

Authors: Molina-Pimienta L, Cuellar A, Tapiero-Garcia M, Romero-Rojas A, Sanchez-Castillo J,

Keywords: neuroendocrine tumour, Kaplan-Meier analysis, middle-income countries, epidemiology,

#4161 177Lu-DOTATATE (177Lu) efficacy in metastatic well-differentiated neuroendocrine tumors (wdNET): Differences in response according to metastases (met) location

Introduction: Treatment with 177Lu is standard of care for wdNET with high somatostatin receptor expression. Patterns of response could differ between hepatic (hep) and extrahepatic (ehep) met.

Conference:

Presenting Author:

Authors: Sánchez Gómez L, Guillén Sentís P, Ruffinelli J, Torrent F, Vercher Conejero J,

Keywords: 177lu-dotatate, well-differentiated neuroendocrine tumor, tumor growth rate,

#3842 Long response to 177-Lu DOTATATE of a long malignant metastatic pheochromocytoma survivor

Introduction: A 64-year-old man was admitted on November 2010 with a CT-scan showing a 9cm right adrenal mass and high 24-hour urine metanephrins and cathecolamins. The mass was resected in December 2010 confirming a pT3N1 pheochromocytoma (PHEO). In May 2013 he presented a local recurrence that was resected proving metastatic lymphatic tissue. On May 2014 biochemical progression preceded a CT scan showing retroperitoneal lymphadenophaties with MIBG uptake. He was then treated with 131I-MIBG (two cycles) until May 2015, having biochemical and radiological response. After lymphatic tumor progression in January 2018, he received two more cycles of 131I-MIBG therapy (cumulative dose 800mCi) with proven refractory disease. He continued follow-up until two new abdominal masses appeared in October 2020. A high uptake in the 99Tc octreotide scintigraphy showed somatostatin receptors expression. The patient refused to participate in a clinical trial, so he was treated off-label with 177Lu-DOTATATE (800mCi) four doses from February to July 2021 achieving a near-complete response.

Conference:

Presenting Author: Martin Fernandez de Soignie A

Authors: Martin Fernandez de Soignie A, Martinez Moreno E, Antón-Pascual B, Pantin Gonzalez C, Sanchez Baños N,

Keywords: pheochromocytoma, 177-Lutetium,